3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
4
Breast Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Metastatic Solid Tumors
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Glioblastoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Hepatocellular
1
Interventions
tislelizumab
4
talazoparib
4
pembrolizumab
4
Docetaxel
4
Nivolumab
3
PM 01183
2
MLN 8237
2
Itraconazole
2
Fluorouracil
2
Cisplatin
2
Carboplatin
2
zimberelimab
1
utomilumab
1
urelumab
1
ulixertinib
1
trifluridine tipiracil drug combination
1
sitravatinib
1
sapanisertib
1
pexidartinib
1
pevonedistat
1
peposertib
1
niraparib
1
mogamulizumab
1
lenvatinib
1
ixabepilone
1
eribulin
1
durvalumab
1
dalotuzumab
1
avelumab
1
ascrinvacumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Advanced Solid Tumors
×
sacituzumab govitecan
×
Clear all
No trials found.